The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Hematologic Cancer
HEMATOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
BEGEV Salvage Regimen Linked to High Complete Remission Rates
5-year results from that a study on BEGV have confirmed its benefits in classical Hodgkin lymphoma. -
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments. -
Current and Prospective Treatment Options for Waldenström Macroglobulinemia
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia. -
Oral Oncology Parity Laws Don’t Make Medications More Affordable
Out-of-pocket spending remains high for many patients with blood cancers who are receiving tyrosine kinase inhibitors and immunomodulatory drugs.
HEMATOLOGIC CANCER NEWS
Intensive Immunochemotherapy May Yield Positive Outcomes in Burkitt Lymphoma
Best Practices for Diagnosing Breast Implant-Associated Anaplastic Large Cell Lymphoma
Priority Review Granted to Tazemetostat for Follicular Lymphoma Indication
Comparing Cost-Effectiveness of First-Line Treatment Approaches for Hodgkin Lymphoma
Single-Agent Daratumumab May Delay Progression of Smoldering Multiple Myeloma
Want to read more?
Please login or register first to view this content.
Next post in Hematologic Cancers
